Meeting 2: Patient and Care Partner Perspectives on Early Enrollment into Gene Therapy Clinical Trials for Rare Diseases
The FDA held a meeting to collect perspectives from patients and care partners regarding early enrollment in gene therapy clinical trials for rare diseases. Discussions focused on the role of trials in informing risk-benefit decisions and the necessity of long-term follow-up for assessing safety and durability.
Sponsors of gene therapies for rare diseases, clinical trial investigators, and regulatory professionals involved in trial design and patient recruitment strategies.
The emphasis on patient perspectives suggests that the FDA is prioritizing patient-centric data in evaluating the benefit-risk profile of gene therapies. The focus on long-term follow-up indicates that durability and delayed safety signals remain primary regulatory concerns, which may influence post-market requirements and data collection duration requirements for rare disease therapies.
Sponsors should evaluate long-term follow-up protocols to ensure they sufficiently capture safety and durability data. Clinical teams may need to refine informed consent processes to explicitly address the balance of uncertainty regarding risks and benefits in early-enrollment gene therapy trials.
Gene therapy trials inform risks & benefits for informed decisions. Long-term follow-up crucial for safety & durability assessment.
Open in openFDA / FDA.gov